Cytel Joins DIA Discussion on Predictive Enrichment Strategies

Posted by Cytel Consulting

May 16, 2014 2:48:00 PM


Cytel Consulting's Zoran Antonijevic

The key focus of precision medicine is identification of patients who would most benefit from a treatment. Proper enrichment of patient population greatly improves the probability of regulatory approval as well as product differentiation through improved efficacy and safety. Greater product differentiation leads to greater market access, as reimbursement is now a key driver to commercial success.

The process from observing a first signal of improved treatment response to demonstrating this in late stage clinical trials is very challenging, as described in the FDA Draft Guidance on Enrichment Strategies for Clinical Trials, published in December 2012. Zoran Antonijevic from Cytel Consulting will be presenting at the DIA Annual Meeting in a session “Predictive Enrichment: Design, Development Strategies, and Methodological Issues."

In his talk Zoran will go over considerations for incorporation of predictive biomarkers at late stage drug development. He will describe drug development strategies and clinical trial designs, including adaptive enrichment designs, that deal with this complex topic. Cytel Consulting has experience with both the methodology and the design of adaptive enrichment trials. Zoran’s presentation will illustrate one such case study. 

In addition to his role as a Senior Director at Cytel  Consulting, Zoran also chairs the DIA's Adaptive Design Scientific Working Group. 


Related Items of Interest

FDA Draft Guidance on Enrichment Strategies for Clinical Trials

Click here to learn about Cytel Consulting



Topics: Enrichment, Cytel Consulting, Adaptive Clinical Trials

The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.


Posts by Topic

see all

Recent Posts